Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
13
1
1
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
46%
6 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (13)
Changes Associated With H. Pylori and Gastric Carcinogenesis
Helicobacter Eradication Aspirin Trial
The Impact of Helicobacter Pylori Infection on Immune Regulation and Clinical Course in HIV Patients in Ghana
Bleeding Ulcer and Erosions Study "BLUE Study"
Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection
Epidemiology of Helicobacter Pylori Infection Among Shanghai Children
Reinfection After Eradication of Helicobacter Pylori Infection
Resistance of Helicobacter Pylori to Antibiotics in Children
Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding
POCone-UBiT-IR300 Pediatric Comparison Study
RCT: Triple vs Sequential vs Concomitant Therapy H Pylori
Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy